Discontinued Product(±)-Chlorpheg (Cat. No. 0134) has been withdrawn from sale for commercial reasons.
Selective L-homocysteate uptake inhibitor. See separate isomer (Cat. No. 0817).
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
References are publications that support the biological activity of the product.
Davies et al (1985) Selective potentiating effect of b-p-chlorophenylglutamate on responses induced by certain sulphur-containing excitatory amino acids and quisqualate. Neuropharmacology. 24 177 PMID: 3887200
Ito et al (1991) L-Homocysteic acid mediates synaptic excitation at NMDA receptors in the hippocampus. Neurosci.Lett. 124 157 PMID: 1676834
View Related Products by Product Action
Keywords: (±)-Chlorpheg, (±)-Chlorpheg supplier, Glutamate, Transporters, 0134, Tocris Bioscience
Citations for (±)-Chlorpheg
Citations are publications that use Tocris products.
Currently there are no citations for (±)-Chlorpheg.
Reviews for (±)-Chlorpheg
There are currently no reviews for this product. Be the first to review (±)-Chlorpheg and earn rewards!
Have you used (±)-Chlorpheg?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.